© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Ozagrel Methyl Ester stands as a distinct chemical compound featuring potential applications within both pharmaceutical research and industrial chemical manufacturing. Its identity traces to a unique molecular structure crafted for specific anti-thrombotic and anti-platelet activity in drug development. Over years of research, compounds like Ozagrel and its derivatives have drawn the attention of scientists for their role in managing cardiovascular events linked to thrombus formation. Ozagrel Methyl Ester typically comes as a white to off-white solid when kept under ambient conditions, revealing itself in several physical forms such as powder, crystalline flakes, or occasionally, compact pearls. Original studies into the parent compound’s action as a thromboxane A2 synthase inhibitor opened doors to a wave of analogues, and methyl ester continues to prove its importance thanks to its solubility and chemical stability.
This compound shows notable chemical properties that separate it from related esters and intermediates. With a molecular formula of C15H16N2O4, Ozagrel Methyl Ester achieves a blend between structure and function, where its aromatic rings and methyl ester group decide both behavior and reactivity profile. The density hovers near 1.3 g/cm³, and in laboratory settings, it retains its form even with minor temperature fluctuations. Solid at room temperature, it easily transitions to solution for experimental or manufacturing needs. The powder tends to clump if exposed to humidity, and its solubility in polar organic solvents remains high compared to other esterified samples in this chemical category. As a material, the compound emits low to moderate odor; it resists spontaneous oxidation but reacts with strong acids and bases. When handled in quantities exceeding a few grams, lab workers notice its fine dust, which can irritate the mucosa, so reliable protective procedures come into play.
Closer examination through NMR and IR spectroscopy highlights the building blocks of Ozagrel Methyl Ester. The molecule features an esterified methyl group attached to a benzothiazole-derived backbone, granting it both rigidity and reactive sites for downstream synthesis. Each unit fits together in a shape suited to chemical modification, a trait pharmaceutical teams favor for new prodrug creation. Visualized crystalline samples show distinct, plate-like facets under the microscope. Bulk product often contains nil water and less than one percent organic impurities, measured against standard HPLC methods. Granular size varies based on manufacturer—ranging from coarse powder suited for bulk shipment to fine crystals designed for rapid solvation and pharmaceutical processes.
In practice, the safety profile of Ozagrel Methyl Ester deserves close attention. While it lacks strong volatility or explosive risk under standard storage, extended inhalation or skin contact can cause discomfort and reddening, especially with sensitive individuals. The labeling usually displays standard hazard pictograms in line with global GHS guidelines, warning of the chemical’s possible local irritant effects. Direct ingestion spells harmful outcomes, so GLP (Good Laboratory Practice) calls for gloves, goggles, and particulate masks during weighing or solution preparation. The compound neither degrades rapidly nor emits noxious gases upon light thermal exposure, though open flames or oxidizing agents can break it down, releasing nitrogen oxides and other lower-molecular-weight organics. Disposing of leftover material means collecting solids in sealed containers, followed by certified chemical waste routes instead of casual sewer drainage. Regulatory details tie into the HS Code for specialized organic chemicals, generally falling within 2921.49 or similar for customs declarations.
Bringing Ozagrel Methyl Ester to market involves mastery of synthesis from base compounds like benzothiazole derivatives and methylating agents, sourced from chemical suppliers following REACH compliance in Europe and similar track records worldwide. High purity grades cater to pharmaceutical use, supporting research into vascular and platelet-related disorders, all while lab teams rely on batch-to-batch certificates of analysis confirming identity, purity, and molecular weight. Beyond bench-scale synthesis, larger contract manufacturing outfits invest in reactor systems keeping product free of metallic residues and moisture, as required by strict drug agency audits. Since the compound’s history ties deeply to medicinal chemistry, many universities and R&D sites seek out the substance in multi-kilogram lots, used for both reference standards and synthetic intermediates. Supply chains, especially in the last decade, face scrutiny on environmental impact and worker safety around production, nudging the industry toward greener solvents and closed handling systems.
Production and distribution raise questions that stretch beyond technical specifications. Many research labs hunt not just for ozagrel methyl ester alone, but for documentation showing source reliability, impurity profiles, and full traceability—requirements accelerated by regulatory clampdowns after adverse events involving counterfeit supply in the broader pharmaceutical industry. Current gaps between supplier transparency and user needs could shrink if manufacturers prioritized real-time batch tracking systems, more accessible digital safety sheets, and clear feedback channels for reporting shipment quality issues on arrival. Distribution chains that plan for rapid customs clearance based on harmonized international coding (HS Code) reduce costly delays, ensuring stable access to ozagrel derivatives for clinical and lab end-users. Education remains vital among chemical handlers, not simply around acute exposure risks but on slower, cumulative health effects, emphasizing medical screenings and upgrades to ventilation where large-batch processing occurs.
Direct experience in the field shows the importance of integrating chemical stewardship into every step, from initial synthesis through long-term storage. Ozagrel Methyl Ester’s safety envelope, robust in designed settings, swiftly unravels if teams dismiss protective steps or skip training. Companies advancing sustainable solutions experiment with biodegradable solvents and more energy-efficient crystallization processes, scraping away at the environmental load of classical organic chemistry labs. Looking at future trends, pairing legacy strengths—strong efficacy and chemical resilience—with clear, accessible hazard communication could help users handle ozagrel methyl ester responsibly and with minimal ecological footprint. By pooling shared experience from chemists, safety officers, and environmental scientists, the industry stands poised to keep both product integrity and handler well-being as durable pillars in the ongoing journey of new drug discovery.
